Sign in
ENTA Stock Price, Chart, Stats & News
Enanta Pharmaceuticals, Inc.
Save
312.26M
Market cap
–
Current P/E
44.05x
Forward P/E
ENTA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -109.08% |
Pretax margin | -108.62% |
Net margin | -106.80% |
Effective tax rate | 1.68% |
ROA | -21.71% |
ROE | -78.59% |
D/E | 1.53x |
Interest coverage ratio | -8.30x |
ENTA valuation
P/E | – |
P/S | 4.22x |
P/B | 2.06x |
P/CF | -18.38x |
P/FCF | -15.32x |
P/OCF | -18.38x |
PEG | -0.29x |
EV multiple | -2.15x |
About
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories.
Similar securities
Based on sector and market capitalization
Report issue